Clinical Trial Update: Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating safety and efficacy of pimecrolimus ophthalmic suspension in moderate to severe keratoconjunctivitis sicca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconjunctivitis Sicca

Drugs mentioned

• pimecrolimus ophthalmic suspension (pimecrolimus)

Snippet

Sponsor: Novartis | Conditions: Keratoconjunctivitis Sicca | Phase 2 | Status: COMPLETED